[ad_1]
The US pharmaceutical company Pfizer (PFE) and German partner BioNTech (BNTX) applied for the emergency use of a new vaccine against coronavirus infection (Corona 19) to the US Food and Drug Administration (FDA) on the day 20 (local time) did.
The FDA approval process for Pfizer vaccines is expected to take several weeks, according to CNBC, a US economic news outlet, and an advisory committee meeting to review the vaccine is scheduled for early December.
Pfizer and Bioentech stock prices rose 9.63% and 1.41%, respectively.
If Pfizer’s application is approved, the vaccine will be distributed in stages. Healthcare workers, the elderly, and people with underlying medical conditions receive the first dose. Essential workers, teachers and people in homeless shelters and prisons are likely to be the next target, and children and young adults will follow suit, CNBC said.
Albert Bourla, Chief Executive Officer (CEO) of Pfizer, issued a statement that day, saying, “This app will be an important milestone in our journey of global distribution of the COVID-19 vaccine.” “We are now looking at the efficacy and safety of the vaccine.” I have a more complete understanding and feel confident about its potential. “
Pfizer said it expects the FDA to approve the emergency use by the middle of next month and, if approved, it will begin distribution immediately.
Pfizer plans to prepare 50 million doses of the vaccine this year, which can be administered by 2.5 billion people.
Meanwhile, the UK has also entered the approval process for Pfizer’s vaccine.
According to foreign media such as Reuters on the day, British Health Minister Matt Hancock said: “The first step for a vaccine license in the UK is for the government to formally request a conformity assessment from the independent regulatory body, the Products Regulatory Authority. Pharmaceutical and Healthcare (MHRA) “. -We have submitted such a request for the bioentech vaccine. “
“This is a very important step in responding to the pandemic,” Hancock said. “If the vaccine is approved, it will certainly be available free of charge across the UK through the National Health Service (NHS).”
Taejun Lee, Global Economic Reporter [email protected]
[알림] This article is for reference only in investment decisions, and there is no liability for investment losses based on this.
